ArticleFrontiers in immunology2026
Clinical immunology in chromatinopathies: a scoping review.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chromatinopathies (CP) are a subclass of monogenic neurodevelopmental disorders caused by germline mutations in genes involved in epigenetic regulation. Symptoms may include neurodevelopmental delay, intellectual disability, autism spectrum disorder, facial dysmorphisms, growth abnormalities, and various congenital anomalies. These disorders often also present with immunopathology. However, a clear insight into immune dysregulation in CPs is currently unavailable. Objective: This scoping review aims to synthesize clinical data on anomalies of the immune system, including laboratory values and medical history of individuals with CPs, to fill knowledge gaps. Methods: Articles on immunological aspects in individuals with CPs, caused by germline mutations affecting chromatin-modifying enzymes from the "writers" group, were included. Searches were conducted using PubMed, Cochrane Library, and Web of Science until March 30, 2024 and articles after that date were added as cross-referenced. Results: 101 articles covering 715 individuals with 21 different syndromes were included. In all CPs, frequent infections, mainly of the respiratory tract, were reported. Moreover, common immunopathology included immunodeficiency and immune thrombocytopenic purpura. Immunologic laboratory results were available for a total of 183 individuals with ten different syndromes. Hypo/a-gammaglobulinemia was present in the majority of these individuals. The most characterized and affected syndromes were ICF syndrome type 1 and Kabuki syndrome type 1. Conclusion: Despite common immune manifestations, systematic laboratory tests on immune characteristics are not commonly performed for the majority of CP cases. To better understand the role of immune dysfunction in the pathology of CPs and offer treatment strategies, standardized guidelines for clinicians need to be established. Systematic Review Registration: https://inplasy.com/wp-content/uploads/2025/12/INPLASY-Protocol-8609.pdf, identifier INPLASY2025120066.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.